Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
May 09 2017 - 8:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing CODIT™ (Characterized Oral
Desensitization ImmunoTherapy) treatments for
life-threatening food allergies, today announced that CEO Stephen
Dilly, M.B.B.S., Ph.D., will present a company overview at the Bank
of America Merrill Lynch Healthcare Conference in Las Vegas on
Tuesday, May 16, at 1:00 p.m. Pacific Time.
The live webcast of the presentation will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. The replay of the webcast will be
available for at least 30 days following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized
Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of
protection by desensitizing patients with defined, precise amounts
of key allergens. Aimmune’s first investigational product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a
characterized, regulated, oral biological drug product containing
the protein profile found in peanuts. For more information, please
see www.aimmune.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509005531/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2023 to Apr 2024